- Home
- PB vs ACLX Comparison
PB vs ACLX Comparison
Compare PB & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$115.08
Company Overview
Basic Information| Metric | PB | ACLX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.7B |
| IPO Year | 1998 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PB | ACLX |
|---|---|---|
| Price | $69.16 | $115.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 15 |
| Target Price | $79.00 | ★ $118.17 |
| AVG Volume (30 Days) | 782.7K | ★ 5.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 13.27 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $41.06 | $342.39 |
| Revenue Next Year | $17.07 | $170.71 |
| P/E Ratio | $59.70 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $61.07 | $60.36 |
| 52 Week High | $77.20 | $115.14 |
Technical Indicators
Market Signals| Indicator | PB | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 79.86 |
| Support Level | $68.11 | $63.46 |
| Resistance Level | $70.52 | N/A |
| Average True Range (ATR) | 1.37 | 0.11 |
| MACD | 0.06 | -0.62 |
| Stochastic Oscillator | 65.24 | 84.28 |
Price Performance
Historical Comparison PB
ACLX
About PB Prosperity Bancshares Inc.
Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.